1 month Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q3 Loss Zacks
Cyclacel Pharmaceuticals (CYCC) delivered earnings and revenue surprises of 66.67% and 0%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
X